FDA Clears Pharmaxis Cancer Drug to Progress to Phase 2 Study in Liver Cancer
9th
Nov 21
Release Date: 09/11/2021 8:45am
- IND approved to trial PXS-5505 added to current standard of care in newly diagnosed unresectable hepatocellular carcinoma patients
- University of Rochester Medical Center and Pharmaxis in discussions to commence investigator-led study in 2022
Categories: News and Media